HOME
HIV and AIDS
Hepatitis B
Hepatitis C
HIV-HCV Coinfection
HIV-HBV Coinfection
HIV and AIDS Articles
  FDA-approved Treatments
  Experimental Treatments
  Top New Articles
  Guidelines
HOME PAGE

Elvitegravir (GS-9137)

Gilead Announces Start of Phase III Efficacy Trial of Experimental Integrase Inhibitor Elvitegravir in Treatment-experienced HIV Patients - 7/25/08

Ritonavir-boosted Elvitegravir Has Potent and Durable Activity in Treatment-experienced Patients with Active Optimized Background Therapy - 9/26/07

Lack of Clinically Relevant Drug Interactions Between Ritonavir-boosted Elvitegravir and Experimental NNRTI Etravirine (TMC125) - 9/26/07

Experimental Integrase Inhibitor Elvitegravir Has Additive to Synergistic Interactions with Other Antiretrovirals in vitro and No Relevant PK Drug Interaction with Darunavir/ritonavir or Tipranavir/ritonavir - 8/03/07

Integrase Inhibitor Elvitegravir from Gilead Sciences Demonstrates Potent and Durable Activity at 24-weeks in Treatment-experienced HIV Patients - 3/06/07

In Vitro Resistance Profi le of HIV-1 Mutants Selected by the HIV-1 Integrase Inhibitor, GS-9137 (JTK-303)
G Jones and others. Poster 627 (PowerPoint).  - 3/16/07

The HIV Integrase Inhibitor GS-9137 Has Potent Antiretroviral Activity in Treatment-Experienced Patients
A Zalopa and others. Poster 505 (PowerPoint).  - 3/16/07


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Protease Inhibitors
Agenerase (amprenavir)
Aptivus (tipranavir)
Crixivan (indinavir)
Invirase (saquinavir hard gel)
Kaletra (lopinavir/ritonavir)
Lexiva (fosamprenavir)
Norvir (ritonavir)
Prezista (darunavir)
Reyataz (atazanavir)
Viracept (nelfinavir)
Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
Combivir (zidovudine/lamivudine)
Epivir (lamivudine; 3TC)
Emtriva (emtricitabine; FTC)
Epzicom (abacavir + lamivudine)
Retrovir (zidovudine; AZT)
Trizivir (abacavir + zidovudine +lamivudine)
Truvada  (tenofovir / emtricitabine)
Videx (didanosine; ddI)
Viread (tenofovir)
Zerit (stavudine; d4T)
Ziagen (abacavir)
non Nucleoside Reverse
Transcriptase Inhibitors
Etravirine (Intelence; TMC125)
Rescriptor (delavirdine)
Sustiva (efavirenz)
Viramune (nevirapine)
Entry Inhibitors
(including Fusion Inhibitors)
Fuzeon (enfuvirtide, T-20)
Selzentry ( maraviroc)
Fixed-dose Combinations
Atripla (efavirenz + emtricitabine + tenofovir)
Combivir (zidovudine + lamivudine)
Trizivir (abacavir + zidovudine + lamivudine)
Truvada (tenofovir + emtricitabine)
Integrase Inhibitor
Isentress (raltegravir)